![Han Jing Xie](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Han Jing Xie
Chief Tech/Sci/R&D Officer at
Idogen AB
Profile
Han Jing Xie is an Associate Professor at Karolinska Institutet and the Chief Medical Officer at Idogen AB. Prior to these roles, Xie was a Senior Director-Medical Study at Oncopeptides AB and the Head-Cancer Clinical Trial Unit at Capio St Gorans Hospital.
Xie earned a doctorate degree from Karolinska Institutet in 2004.
Han Jing Xie active positions
| Companies | Position | Start |
|---|---|---|
Idogen AB
 Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Chief Tech/Sci/R&D Officer | 01/01/2022 |
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Former positions of Han Jing Xie
| Companies | Position | End |
|---|---|---|
| ONCOPEPTIDES AB | Corporate Officer/Principal | 01/01/2022 |
Capio St Gorans Hospital | Corporate Officer/Principal | 01/01/2020 |
Training of Han Jing Xie
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
87
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Idogen AB
Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Health Technology |
Capio St Gorans Hospital |
- Stock Market
- Insiders
- Han Jing Xie
